Latest & greatest articles for preeclampsia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on preeclampsia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on preeclampsia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for preeclampsia

41. Advocacy is essential to supporting women with pre-eclampsia Full Text available with Trip Pro

Advocacy is essential to supporting women with pre-eclampsia Advocacy has a critical role in advancing the maternal health agenda. Patient advocacy groups can hold governments and other stakeholders accountable and ensure that commitments are translated into concrete action. This article highlights the advocacy efforts of the Preeclampsia Foundation, a patient advocacy organisation that aims to improve the diagnosis, management, and prevention of pre-eclampsia through research and improved

2017 Obstetric medicine

42. Preeclampsia: Screening

page should be cited as the source. References: 1. Ananth CV, Keyes KM, Wapner RJ. Pre-eclampsia rates in the United States, 1980-2010: age-period-cohort analysis. BMJ . 2013;347:f6564. 2. Myatt L, Roberts JM. Preeclampsia: syndrome or disease? Curr Hypertens Rep . 2015;17(11):83. 3. Redman C. Pre-eclampsia: a complex and variable disease. Pregnancy Hypertens . 2014;4(3):241-2. 4. Henderson JT, Thompson JH, Burda BU, Cantor A, Beil T, Whitlock EP. Screening for Preeclampsia: A Systematic Evidence (...) complications, including stroke, eclampsia, and organ failure. Adverse perinatal outcomes for the fetus and newborn include intrauterine growth restriction, low birth weight, and stillbirth. Many of the complications associated with preeclampsia lead to early induction of labor or cesarean delivery and subsequent preterm birth. Detection Obtaining blood pressure measurements to screen for preeclampsia could allow for early identification and diagnosis of the condition, resulting in close surveillance

2017 U.S. Preventive Services Task Force

43. Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis

Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid (...) to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis Frampton G K, Jones J, Rose M & Payne L Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Frampton G K, Jones J, Rose M & Payne L. Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women

2017 Health Technology Assessment (HTA) Database.

44. The Relationship Between Blood Lead Level and Preeclampsia Full Text available with Trip Pro

The Relationship Between Blood Lead Level and Preeclampsia Lead is a heavy metal to which people are commonly exposed. One of the possible mechanisms of tissue damages caused by this toxic metal is oxidative stress, which in turn may cause numerous pregnancy complications such as preeclampsia. The present study was conducted to determine the relationship between maternal Blood Lead Level (BLL) and preeclampsia.The present case-control study was conducted on 158 pregnant women admitted (...) in the control group and 8.04±3.4 μg/dl in the preeclampsia group. The two groups were matching in terms of the mother's age and education and the household income. A significant relationship was observed between BLL and preeclampsia (p=0.028), as per every unit of increase (1 μg/dl) in BLL, systolic blood pressure increased by 0.014 mm Hg and diastolic blood pressure by 0.013 mm Hg (p=0.004).The results obtained suggest a relationship between BLL and preeclampsia. Global health measures should be taken

2016 Electronic physician

45. The evaluation of serum homocysteine, folic acid, and vitamin B12 in patients complicated with preeclampsia Full Text available with Trip Pro

The evaluation of serum homocysteine, folic acid, and vitamin B12 in patients complicated with preeclampsia Increased plasma homocysteine may be associated with adverse pregnancy outcomes, such as preeclampsia. The aim of this study was to determine the plasma homocysteine, serum folate, and vitamin B12 levels in preeclamptic pregnant women.This case-control study was conducted in 2016 in Ahwaz on 51 pregnant women with preeclampsia and 51 healthy pregnant women of the same gestational age, who (...) served as controls. The case group also was subdivided into severe and non-severe preeclampsia. Patients' data were collected through a questionnaire and medical records. Serum homocysteine, folic acid, and vitamin B12 were analyzed using chemiluminescent assay. The results were compared between two groups. Statistical analyses were done using IBM-SPSS 20.0. A Kolmogorov-Smirnov test, independent samples t-test, Mann-Whitney test, and Chi-square test were used for data analysis.No different

2016 Electronic physician

46. The impact of an educational pamphlet on knowledge and anxiety in women with preeclampsia. Full Text available with Trip Pro

to an intervention group (who received a pamphlet) or a control group (who did not received a pamphlet). The pamphlet and questionnaire, both designed by a multidisciplinary team, were read and answered at the same time.Baseline and demographic characteristics were similar between the two groups. Knowledge about the symptoms of pre-eclampsia was excellent in both groups (61% to 100% correct answers). Women in both groups were well aware that preeclampsia in the past (P = 0.22) and a family history (...) The impact of an educational pamphlet on knowledge and anxiety in women with preeclampsia. This study was undertaken to evaluate whether or not an educational pamphlet could improve knowledge without increasing anxiety in women with preeclampsia.One hundred women recruited from an inpatient setting with suspected or proven preeclampsia were asked to answer a questionnaire assessing demographics, knowledge (primary outcome), anxiety and satisfaction (secondary outcomes) after being randomized

2016 Obstetric medicine Controlled trial quality: uncertain

47. LMWH in the prevention of preeclampsia and fetal growth restriction in women without thrombophilia. A systematic review and meta-analysis Full Text available with Trip Pro

LMWH in the prevention of preeclampsia and fetal growth restriction in women without thrombophilia. A systematic review and meta-analysis Placental mediated pregnancy complications such as preeclampsia and fetal growth restriction (FGR) are common, serious, and associated with increased morbidity and mortality. We conducted a systematic review and meta-analysis to determine the effect of treatment with low-molecular-weight heparins (LMWHs) for secondary prevention of these complications in non (...) thrombophilic women. We searched the electronic databases PubMed, Scopus, and Cochrane Library for randomised controlled trials addressing this question. Five studies including 403 patients met the inclusion criteria, 68 developed preeclampsia and 118 FGR. The studies were very heterogeneous in terms of inclusion criteria, LMWH preparation, and dosage. Meta-analyses were performed using random-effect models. The overall use of LMWHs was associated with a risk reduction for preeclampsia (Relative risk (RR

2016 EvidenceUpdates

48. Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor Ratio and Time to Delivery in Women With Suspected Preeclampsia Full Text available with Trip Pro

Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor Ratio and Time to Delivery in Women With Suspected Preeclampsia To assess the association of a serum soluble fms-like tyrosine kinase 1-to-placental growth factor (sFlt-1-to-PlGF) ratio of greater than 38 with time to delivery and preterm birth.Secondary analysis of an observational cohort study that included women 18 years of age or older from 24 to 36 6/7 weeks of gestation at their first study visit with suspected (not confirmed (...) ) preeclampsia. Participants were recruited from December 2010 to January 2014 at 30 sites in 14 countries. A total of 1,041 women were included in time-to-delivery analysis and 848 in preterm birth analysis.Women with an sFlt-1-to-PlGF ratio greater than 38 (n=250) had a 2.9-fold greater likelihood of imminent delivery (ie, delivery on the day of the test) (Cox regression hazard ratio 2.9; P<.001) and shorter remaining time to delivery (median 17 [interquartile range 10-26] compared with 51 [interquartile

2016 EvidenceUpdates

49. Perinatal and Hemodynamic Evaluation of Sildenafil Citrate for Preeclampsia Treatment: A Randomized Controlled Trial Full Text available with Trip Pro

Perinatal and Hemodynamic Evaluation of Sildenafil Citrate for Preeclampsia Treatment: A Randomized Controlled Trial To evaluate whether therapy with sildenafil citrate prolongs gestation in women with preeclampsia.In a randomized double-blind, placebo-controlled trial, 100 singleton pregnancies with preeclampsia between 24 and 33 weeks of gestation were randomized to 50 mg oral sildenafil citrate every 8 hours or placebo. The primary outcome was prolongation of pregnancy from randomization

2016 EvidenceUpdates Controlled trial quality: predicted high

50. The impact of Silymarin on improvement of platelet abnormalities in patients with severe preeclampsia. Full Text available with Trip Pro

The impact of Silymarin on improvement of platelet abnormalities in patients with severe preeclampsia. Preeclampsia is a pregnancy-specific disorder that is associated with an increase in blood pressure and proteinuria; in severe cases, it can cause platelet abnormalities. Silymarin is the extract of Silybum marianum, which is recognized as a safe antioxidant drug.To determine the impact of Silymarin on the improvement of severe preeclampsia in 60 patients with severe preeclampsia.In (...) this double-blind clinical trial study, This study included 60 patients whose pregnancies were terminated because of severe preeclampsia and who were referred to Hajar Hospital in Shahrekord, Iran, from April 2014 to September 2015. The patients were divided randomly into two groups, i.e., a group of 30 patients and a control group of 30 patients. In addition to the current treatments for preeclampsia, The members of the study group were administered 70 mg of Silymarin at three hours and 24 hours after

2016 Electronic physician Controlled trial quality: uncertain

51. Protective Role of Maternal P.VAL158MET Catechol-O-Methyltransferase Polymorphism against Early-Onset Preeclampsia and its Complications Full Text available with Trip Pro

Protective Role of Maternal P.VAL158MET Catechol-O-Methyltransferase Polymorphism against Early-Onset Preeclampsia and its Complications Up until now there have been contradictory data about the association between p.Val158Met catechol-O-methyltransferase (COMT) polymorphism and risk of preeclampsia (PE). The goal of this study was to assess the potential correlation between p.Val158Met COMT polymorphism and risk of early-onset PE, risk of a severe form of early-onset PE, as well as risk

2016 Journal of medical biochemistry

52. The performance of risk prediction models for pre-eclampsia using routinely collected maternal characteristics and comparison with models that include specialised tests and with clinical guideline decision rules: a systematic review Full Text available with Trip Pro

The performance of risk prediction models for pre-eclampsia using routinely collected maternal characteristics and comparison with models that include specialised tests and with clinical guideline decision rules: a systematic review Risk prediction models may be valuable to identify women at risk of pre-eclampsia to guide aspirin prophylaxis in early pregnancy.To assess the performance of 'simple' risk models for pre-eclampsia that use routinely collected maternal characteristics; compare (...) with 'specialised' models that include specialised tests; and to guideline recommended decision rules.MEDLINE, Embase and PubMed were searched to June 2014.We included studies that developed or validated pre-eclampsia risk models using maternal characteristics with or without specialised tests and reported model performance.We extracted data on study characteristics; model predictors, validation and performance including area under the curve (AUC), sensitivity and specificity.We identified 29 studies

2016 EvidenceUpdates

53. First trimester screening for pre-eclampsia Full Text available with Trip Pro

First trimester screening for pre-eclampsia The commercial availability of tests in the first trimester of pregnancy that predict the later development of pre-eclampsia has prompted considerable debate regarding their clinical utility and the degree to which they fulfil the longstanding principles of screening. Such tests have been shown to achieve detection rates for early pre-eclampsia (requiring delivery prior to 34 weeks) of over 90%, for a false positive rate of 10%. However (...) , their capacity to predict later onset pre-eclampsia, which accounts for the bulk of the disease burden, is much more limited. The relatively few studies validating the performance of these tests in different populations have demonstrated significant variations in performance. Moreover, prospective research confirming that the administration of aspirin to those screened to be high risk reduces the incidence of pre-eclampsia is yet to be completed, and there may be harms in restricting aspirin therapy

2016 Obstetric medicine

54. The sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. Full Text available with Trip Pro

26735990 N Engl J Med. 2016 May 5;374(18):1785 27144855 Female Humans Pre-Eclampsia diagnosis Pregnancy Pregnancy Proteins blood Vascular Endothelial Growth Factor Receptor-1 blood 2016 5 5 6 0 2016 5 6 6 0 2016 5 6 6 1 ppublish 27144854 10.1056/NEJMc1602338 10.1056/NEJMc1602338#SA2 (...) The sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. 27144854 2016 05 05 2018 12 02 1533-4406 374 18 2016 05 05 The New England journal of medicine N. Engl. J. Med. The sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. 1785-6 10.1056/NEJMc1602338 Zeisler Harald H Hund Martin M Verlohren Stefan S eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Pregnancy Proteins EC 2.7.10.1 Vascular Endothelial Growth Factor Receptor-1 AIM IM N Engl J Med. 2016 Jan 7;374(1):13-22

2016 NEJM

55. The sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. Full Text available with Trip Pro

daniele.bolla@insel.ch. eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Pregnancy Proteins EC 2.7.10.1 Vascular Endothelial Growth Factor Receptor-1 AIM IM N Engl J Med. 2016 Jan 7;374(1):13-22 26735990 N Engl J Med. 2016 May 5;374(18):1785-6 27144854 Female Humans Pre-Eclampsia diagnosis Pregnancy Pregnancy Proteins blood Vascular Endothelial Growth Factor Receptor-1 blood 2016 5 5 6 0 2016 5 6 6 0 2016 5 6 6 1 ppublish 27144855 10.1056/NEJMc1602338 10.1056/NEJMc1602338#SA1 (...) The sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. 27144855 2016 05 05 2018 12 02 1533-4406 374 18 2016 05 05 The New England journal of medicine N. Engl. J. Med. The sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. 1785 10.1056/NEJMc1602338 Bolla Daniele D University Hospital of Bern, Bern, Switzerland daniele.bolla@insel.ch. Papadia Andrea A University Hospital of Bern, Bern, Switzerland daniele.bolla@insel.ch. Raio Luigi L University Hospital of Bern, Bern, Switzerland

2016 NEJM

56. For Pregnant Women With Periodontitis, Periodontal Therapy Does Not Reduce The Incidence of Pre-eclampsia

thought to be related, none of the RTCs demonstrated a reduction in pre-eclampsia after a successful periodontal treatment was delivered (overall Risk Ratio of pre-eclampsia for the three RCTs=1.0/ 95% Confidence interval =0.78, 1.28). The statistical heterogeneity was not found to be significant, supported with a p value of 0.198. Evidence Search “Periodontal Diseases” [MeSH] OR periodont *gingivitis) AND (“Pre-Eclampsia” [MeSH] OR preeclampsia OR eclampsia OR eclamp* OR proteinuria OR “pregnancy (...) review not only focuses on the prevalence of pre-eclampsia in pregnant women, but also the effect of periodontal treatment during different stages of gestational period to minimize the risk of complications such as preeclampsia. Applicability This evidence based review shows that pregnant women with periodontal disease receiving periodontal therapy will not exhibit a minimized risk of getting complications such as pre-eclampsia. This information is also pertinent to dental practitioners who seek

2016 UTHSCSA Dental School CAT Library

57. Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. Full Text available with Trip Pro

Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. The ratio of soluble fms-like tyrosine kinase 1 (sFlt-1) to placental growth factor (PlGF) is elevated in pregnant women before the clinical onset of preeclampsia, but its predictive value in women with suspected preeclampsia is unclear.We performed a prospective, multicenter, observational study to derive and validate a ratio of serum sFlt-1 to PlGF that would be predictive of the absence or presence (...) of preeclampsia in the short term in women with singleton pregnancies in whom preeclampsia was suspected (24 weeks 0 days to 36 weeks 6 days of gestation). Primary objectives were to assess whether low sFlt-1:PlGF ratios (at or below a derived cutoff) predict the absence of preeclampsia within 1 week after the first visit and whether high ratios (above the cutoff) predict the presence of preeclampsia within 4 weeks.In the development cohort (500 women), we identified an sFlt-1:PlGF ratio cutoff of 38

2016 NEJM

58. Improving the Prediction of Preeclampsia. (Abstract)

Factor Receptor-1 AIM IM N Engl J Med. 2016 Jan 7;374(1):13-22 26735990 Female Humans Pre-Eclampsia diagnosis Pregnancy Pregnancy Proteins blood Vascular Endothelial Growth Factor Receptor-1 blood 2016 1 7 6 0 2016 1 7 6 0 2016 1 21 6 0 ppublish 26735997 10.1056/NEJMe1515223 (...) Improving the Prediction of Preeclampsia. 26735997 2016 01 20 2018 12 02 1533-4406 374 1 2016 Jan 07 The New England journal of medicine N. Engl. J. Med. Improving the Prediction of Preeclampsia. 83-4 10.1056/NEJMe1515223 Seely Ellen W EW From the Endocrinology, Diabetes, and Hypertension Division, Brigham and Women's Hospital, Boston (E.W.S.). Solomon Caren G CG eng Editorial Comment United States N Engl J Med 0255562 0028-4793 0 Pregnancy Proteins EC 2.7.10.1 Vascular Endothelial Growth

2016 NEJM

60. Cohort study: The combination of maternal early pregnancy characteristics and current antenatal blood pressure measurement from 28?weeks? gestation improves the prediction of women at risk of developing pre-eclampsia

Cohort study: The combination of maternal early pregnancy characteristics and current antenatal blood pressure measurement from 28?weeks? gestation improves the prediction of women at risk of developing pre-eclampsia The combination of maternal early pregnancy characteristics and current antenatal blood pressure measurement from 28 weeks’ gestation improves the prediction of women at risk of developing pre-eclampsia | BMJ Evidence-Based Medicine We use cookies to improve our service (...) name or password? You are here The combination of maternal early pregnancy characteristics and current antenatal blood pressure measurement from 28 weeks’ gestation improves the prediction of women at risk of developing pre-eclampsia Article Text Prognosis Cohort study The combination of maternal early pregnancy characteristics and current antenatal blood pressure measurement from 28 weeks’ gestation improves the prediction of women at risk of developing pre-eclampsia Fergus P McCarthy 1 , Louise C

2016 Evidence-Based Medicine